Portal de Murcia

www.portaldemurcia.com

• Home
• Business
• Hotels
• Restaurants
• News
• Advertisement

The Catholic University of Murcia has launched, within its own Research Plan, an extraordinary call to finance research projects that provide solutions to the different problems generated by the COVID19 pandemic.

In this plan, which UCAM finances with its own economic resources, the call for the presentation of projects is biannual, and this year it was not appropriate to carry it out, but given the special situation in which we find ourselves, the president of the University, José Luis Mendoza has decided to open this extraordinary call. The objective of the same is to finance the realization of multidisciplinary scientific studies, not only focused on the health area, but also on other areas such as the economy, workers' rights, data protection, tourism, communication in traditional media and social networks, etc. One of the fundamental premises of this UCAM Extraordinary Plan is that the results of the investigations can be applied immediately to the resolution of different adverse situations caused by the pandemic.

Scientists from other centers, companies and institutions, in addition to those of the University itself, may also join the various research groups that will participate in this program.

Those interested have until May 3 to submit their proposals, which should be addressed to the UCAM Vice President for Research.

You can get more information about it through the mail serinvestigacion@ucam.edu Carlos III Health Institute On the other hand, researchers from the Catholic University have also participated in the call of the Carlos III Health Institute with 8 proposals in areas such as the prediction of survival in COVID19 patients with assisted breathing, development of rapid detection methods for SARS-CoV -2, detection of antivirals against SARS-CoV-2 by supercomputing, development of a CISPR / Cas13 system to cut the viral RNA of SARS-CoV-2 in infected cells, use of a plant extract as an adjunct to the treatment of SARS-CoV -2 to improve the clinical picture of COVID19 patients or study the effect of treating these patients with intravenous immunoglobulins.

Source: UCAM